Publications for Stephen Mulligan
Publications for Stephen Mulligan
2016
Huang, P., Mactier, S., Best, O., Belov, L.,
Kaufman (nee Alexander), K., Pascovici, D.,
Mulligan, S., Christopherson, R. (2016). Protein
profiles distinguish stable and progressive
chronic lymphocytic leukemia. Leukemia &
Lymphoma, in press. <a
href="http://dx.doi.org/10.3109/10428194.2015.
1094692">[More Information]</a>
Huang, P., Mactier, S., Armacki, N., Best, O.,
Belov, L., Kaufman (nee Alexander), K.,
Pascovici, D., Mulligan, S., Christopherson, R.
(2016). Protein profiles distinguish stable and
progressive chronic lymphocytic leukemia.
Leukemia & Lymphoma, 57(5), 1033-1043. <a
href="http://dx.doi.org/10.3109/10428194.2015.
1094692">[More Information]</a>
Li, J., Best, O., Mulligan, S., Fernando, S.
(2016). Serum from a subset of patients with
chronic lymphocytic leukemia and large local
reactions to mosquito bites induces upregulation
of CD63 surface expression on basophils in
atopic donors. Leukemia & Lymphoma, in press.
2015
Hamad, N., Kliman, D., Best, G., Caramins, D.,
Hertzberg, M., Lindeman, R., Porter, R.,
Mulligan, S. (2015). Chronic lymphocytic
leukaemia, monoclonal B-lymphocytosis and
pregnancy: five cases, a literature review and
discussion of management. British Journal of
Haematology, 168(3), 350-360. <a
href="http://dx.doi.org/10.1111/bjh.13134">[Mo
re Information]</a>
Sandhu, S., Mulligan, S. (2015). Ofatumumab
and its role as immunotherapy in chronic
lymphocytic leukemia. Haematologica, 100(4),
411-414. <a
href="http://dx.doi.org/10.3324/haematol.2015.1
24107">[More Information]</a>
Kaufman, K., Jenkins, Y., Alomari, M., Mirzaei,
M., Best, O., Pascovici, D., Mactier, S.,
Mulligan, S., Haynes, P., Christopherson, R.
(2015). The Hsp90 inhibitor SNX-7081 is
synergistic with fludarabine nucleoside via DNA
damage and repair mechanisms in human,
p53-negative chronic lymphocytic leukemia.
Oncotarget, 6(38), 40981-40997. <a
href="http://dx.doi.org/10.18632/oncotarget.571
5">[More Information]</a>
Crassini, K., Stevenson, W., Mulligan, S., Best,
O. (2015). The MEK1/2 inhibitor, MEKi-1,
induces cell death in chronic lymphocytic
leukemia cells under conditions that mimic the
tumor microenvironment and is synergistic with
fludarabine. Leukemia & Lymphoma, 56(12),
3407-3417. <a
href="http://dx.doi.org/10.3109/10428194.2015.
1032963">[More Information]</a>
2014
Huang, P., Best, O., Almazi, J., Belov, L.,
Davies, Z., Majid, A., Dyer, M., Pascovici, D.,
Mulligan, S., Christopherson, R. (2014). Cell
surface phenotype profiles distinguish stable and
progressive chronic lymphocytic leukemia.
Leukemia & Lymphoma, 55(9), 2085-2092. <a
href="http://dx.doi.org/10.3109/10428194.2013.
867486">[More Information]</a>
Mulligan, S., Karlsson, K., Strömberg, M.,
Jonsson, V., Gill, D., Hammerstrom, J.,
Hertzberg, M., McLennan, R., Uggla, B.,
Norman, J., et al (2014). Cladribine prolongs
progression-free survival and time to second
treatment compared to fludarabine and high-dose
chlorambucil in chronic lymphocytic leukemia.
Leukemia & Lymphoma, 55(12), 2769-2777. <a
href="http://dx.doi.org/10.3109/10428194.2014.
893306">[More Information]</a>
Christopherson, R., Mactier, S., Almazi, J.,
Kohnke, P., Best, O., Mulligan, S. (2014).
Mechanisms of action of fludarabine nucleoside
against human raji lymphoma cells. Nucleosides,
Nucleotides and Nucleic Acids: An International
Journal for Rapid Communication, 33(4-6),
375-383. <a
href="http://dx.doi.org/10.1080/15257770.2013.
863334">[More Information]</a>
Adena, M., Houltram, J., Mulligan, S., Todd, C.,
Malanos, G. (2014). Modelling the Cost
Effectiveness of Rituximab in Chronic
Lymphocytic Leukaemia in First-Line Therapy
and Following Relapse. PharmacoEconomics,
32(2), 193-207. <a
href="http://dx.doi.org/10.1007/s40273-013-012
5-7">[More Information]</a>
Hafner, J., Kumar, K., Mulligan, S., Ng, K.
(2014). Multifocal central nervous system
demyelination and Lhermitte's phenomenon
secondary to combination chemotherapy for
chronic lymphocytic leukaemia. Journal of the
Neurological Sciences, 338(1-2), 218-219. <a
href="http://dx.doi.org/10.1016/j.jns.2013.12.032
">[More Information]</a>
Alomari, M., Mactier, S., Kaufman (nee
Alexander), K., Best, O., Mulligan, S.,
Christopherson, R. (2014). Profiling the lipid raft
proteome from human MEC1 chronic
lymphocytic Leukemia Cells. Journal of
Proteomics & Bioinformatics, S7, 005. <a
href="http://dx.doi.org/10.4172/jpb.S7-005">[M
ore Information]</a>
2013
Che, Y., Best, G., Zhong, L., Kaufman (nee
Publications for Stephen Mulligan
Alexander), K., Mactier, S., Raftery, M., Graves,
L., Mulligan, S., Christopherson, R. (2013).
Hsp90 Inhibitor SNX-7081 Dysregulates
Proteins Involved with DNA Repair and
Replication and the Cell Cycle in Human
Chronic Lymphocytic Leukemia (CLL) Cells.
Journal of Proteome Research, 12(4),
1710-1722. <a
href="http://dx.doi.org/10.1021/pr301055y">[M
ore Information]</a>
Best, G., Che, Y., Singh, N., Forsyth, C.,
Christopherson, R., Mulligan, S. (2012). The
Hsp90 inhibitor SNX-7081 synergizes with and
restores sensitivity to fludarabine in chronic
lymphocytic leukemia cells with lesions in the
TP53 pathway: a potential treatment strategy for
fludarabine refractory disease. Leukemia &
Lymphoma, 53(7), 1367-1375. <a
href="http://dx.doi.org/10.3109/10428194.2011.
647310">[More Information]</a>
Freeman, J., Crassini, K., Best, G., Forsyth, C.,
MacKinlay, N., Han, P., Stevenson, W.,
Mulligan, S. (2013). Immunoglobulin G subclass
deficiency and infection risk in 150 patients with
chronic lymphocytic leukemia. Leukemia &
Lymphoma, 54(1), 99-104. <a
href="http://dx.doi.org/10.3109/10428194.2012.
706285">[More Information]</a>
2011
Huang, P., Kohnke, P., Belov, L., Best, G.,
Mulligan, S., Christopherson, R. (2013). Profiles
of surface mosaics on chronic lymphocytic
leukemias distinguish stable and progressive
subtypes. Journal of Pharmacy and
Pharmaceutical Sciences, 16(2), 231-237. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=23958192">[More Information]</a>
Best, O., Crassini, K., Freeman, J., Mulligan, S.
(2013). The clinical significance of
hypogammaglobulinaemia and serum
immunoglobulin G subclass deficiency in
patients with chronic lymphocytic leukaemia
(CLL). Scandinavian Journal Of Infectious
Diseases, 45(9), 729-729. <a
href="http://dx.doi.org/10.3109/00365548.2013.
809477">[More Information]</a>
2012
Almazi, J., Mactier, S., Best, G., Crossett, B.,
Mulligan, S., Christopherson, R. (2012).
Fludarabine nucleoside induces accumulations of
p53, p63 and p73 in the nuclei of human
B-lymphoid cell lines, with cytosolic and
mitochondrial increases in p53. Proteomics Clinical Applications, 6(5-6), 279-290. <a
href="http://dx.doi.org/10.1002/prca.201200003"
>[More Information]</a>
Mulligan, S. (2012). Monoclonal
B-lymphocytosis: reflections and definitions.
Leukemia & Lymphoma, 53(9), 1647-1650. <a
href="http://dx.doi.org/10.3109/10428194.2012.
679938">[More Information]</a>
Huang, P., Best, G., Belov, L., Mulligan, S.,
Christopherson, R. (2012). Surface profiles for
subclassification of chronic lymphocytic
leukemia. Leukemia & Lymphoma, 53(6),
1046-1056. <a
href="http://dx.doi.org/10.3109/10428194.2011.
631370">[More Information]</a>
Henrich, S., Mactier, S., Best, G., Mulligan, S.,
Crossett, B., Christopherson, R. (2011).
Fludarabine Nucleoside Modulates Nuclear
"Survival and Death" Proteins in Resistant
Chronic Lymphocytic Leukemia Cells.
Nucleosides, Nucleotides and Nucleic Acids: An
International Journal for Rapid Communication,
30(12), 1181-1189. <a
href="http://dx.doi.org/10.1080/15257770.2011.
603716">[More Information]</a>
2010
Cassano, C., Mactier, S., Mulligan, S., Belov, L.,
Huang, P., Christopherson, R. (2010). Cladribine
and Fludarabine Nucleoside Change the Levels
of CD Antigens on B-Lymphoproliferative
Disorders. International Journal of Proteomics,
2010 (Article ID 964251), 964251-1-964251-9.
<a
href="http://dx.doi.org/10.1155/2010/964251">[
More Information]</a>
2009
Kohnke, P., Mulligan, S., Christopherson, R.
(2009). Membrane proteomics for leukemia
classification and drug target identification.
Current Opinion in Molecular Therapeutics,
11(6), 603-610. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=20072937">[More Information]</a>
Barber, N., Gez, S., Belov, L., Mulligan, S.,
Woolfson, A., Christopherson, R. (2009).
Profiling CD antigens on leukaemias with an
antibody microarray. FEBS Letters, 583(11),
1785-1791. <a
href="http://dx.doi.org/10.1016/j.febslet.2009.03.
018">[More Information]</a>
2008
Henrich, S., Mactier, S., Crossett, B., Mulligan,
S., Christopherson, R. (2008). Fludarabine
induces differential expression of proteins in
human leukemia and lymphoma cells.
Nucleosides, Nucleotides and Nucleic Acids: An
International Journal for Rapid Communication,
27, 634-640. <a
href="http://dx.doi.org/10.1080/1525777080214
Publications for Stephen Mulligan
2287">[More Information]</a>
2007
Mulligan, S. (2007). Chronic lymphocytic
leukaemia resistant to both fludarabine and
alemtuzumab - Double jeopardy. Leukemia and
Lymphoma, 48(10), 1885-1887. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17917953">[More Information]</a>
2006
Belov, L., Mulligan, S., Barber, N., Woolfson,
A., Scott, M., Stoner, K., Chrisp, J., Sewell, W.,
Bradstock, K., Bendall, L., Sartor, M., Young,
G., Wiley, J., Christopherson, R., et al (2006).
Analysis of human leukaemias and lymphomas
using extensive immunophenotypes from an
antibody microarray. British Journal of
Haematology, 135(2), 184-97. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16939496">[More Information]</a>
Christopherson, R., Stoner, K., Barber, N.,
Belov, L., Woolfson, A., Scott, M., Bendall, L.,
Mulligan, S. (2006). Classification of AML
using a monoclonal antibody microarray.
Methods in molecular medicine, 125, 241-251.
<a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16502589">[More Information]</a>
2005
Belov, L., Huang, P., Chrisp, J., Mulligan, S.,
Christopherson, R. (2005). Screening
microarrays of novel monoclonal antibodies for
binding to T-, B- and myeloid leukaemia cells.
Journal of Immunological Methods, 305(1),
10-19. <a
href="http://dx.doi.org/10.1016/j.jim.2005.07.00
7">[More Information]</a>
2004
Wilson, P., Mulligan, S., Christopherson, R.
(2004). Metabolic Response Patterns Of
Nucleotides In B-Cell Chronic Lymphocytic
Leukaemias To Cladribine, Fludarabine And
Deoxycoformycin. Leukemia Research: clinical
and laboratory studies, 28(7), 725-731.
2003
Belov, L., Huang, P., Barber, N., Mulligan, S.,
Christopherson, R. (2003). Identification of
repertoires of surface antigens on leukemias
using an antibody mircroarray. Proteomics,
3(11), 2147-2154. <a
href="http://dx.doi.org/10.1002/pmic.200300599
">[More Information]</a>